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IrritantThe development of non-animal testing methods for the assessment of skin sensitisation potential is an urgent
challenge within the framework of existing and forthcoming legislation. Efforts have been made to replace
current animal tests, but so far no alternative methods have been developed. It is widely recognised that
alternatives to animal testing cannot be accomplished with a single approach, but rather will require the
integration of results obtained from different in vitro and in silico assays. The argument subjacent to the
development of in vitro dendritic cell (DC)-based assays is that sensitiser-induced changes in the DC phenotype
canbedifferentiated fromthose inducedby irritants. This assumption is derived from theunique capacity ofDC to
convert environmental signals encounteredat the skin intoa receptorexpressionpattern (MHCclass IImolecules,
co-stimulatory molecules, chemokine receptors) and a soluble mediator release proﬁle that will stimulate T
lymphocytes. Since signal transduction cascades precede changes in surface marker expression and cytokine/
chemokine secretion, these phenotypic modiﬁcations are a consequence of a signal transduction proﬁle that is
speciﬁcally triggered by sensitisers and not by irritants. A limited number of studies have addressed this subject
and the present review attempts to summarise and highlight all of the signalling pathways modulated by skin
sensitisers and irritants. Furthermore, we conclude this review by focusing on the most promising strategies
suitable for inclusion into a cell-based in vitro alternative approach to hazard identiﬁcation.Ciências da Saúde, Universidade
80217.
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Allergic contact dermatitis (ACD) is one of the most common
occupational diseases in developed countries and 19.5% of the general
population is sensitive toat least oneallergen (Thyssenet al., 2007).ACD is
88 B.M. Neves et al. / Toxicology and Applied Pharmacology 250 (2011) 87–95the clinical condition caused by an allergic immune response following
skin exposure to a large subset of small reactive chemicals (haptens) that
canbe found in the environment and inmanyhouseholdproducts. A large
number of these chemicals are electrophilic molecules (with the
exception of metals and thiols) that have the ability to bind skin proteins
and form sensitising complexes. Several in vivo methods have been
proven accurate in predicting chemicals that possess skin sensitising
properties, such as the local lymph node assay (Basketter et al., 2002).
However, the skin sensitisation potential is an endpoint that needs to be
assessed within the framework of existing and forthcoming legislation,
namely the7thAmendment to theCosmeticDirective (Directive2003/15/
EC) (EU, 2003) andmore recently the newEuropean Cosmetic Regulation
(on November, 2009) (EC, 2009) that seek to gradually eliminate animal
experiments from the safety and toxicity testing of cosmetic ingredients
and other chemical substances. Theﬁnal cut-off date isMarch 2013,when
cosmetic products containing an ingredient whose safety was tested in
animals will not be allowed for sale in Europe, irrespective of the
availability of alternative non-animal tests. Therefore, the rapid develop-
ment and validation of in vitro testing strategies is a prerequisite to
maintain Europe's competitiveness in the cosmetic industry. Progress in
understanding themechanisms of skin sensitisation and its effects on the
production of cytokines/chemokines by different skin cell types provides
the opportunity to develop in vitro tests as an alternative to in vivo
sensitisation testing. Currently, the most promising alternative in vitro
approaches are based on Langerhans (LC)/dendritic cells (DC) systems,
given thepivotal roleplayedby these cells inACD(Ryanet al., 2007). Since
LC are a relativelyminor population in the epidermis (2 to 5%), several cell
culture protocols have been developed to derive LC-like dendritic cells,
namely, DC derived fromCD34+ progenitors from cord blood, DC derived
from blood monocytes and monocytic cell lines with the capacity to
develop intoDC, suchas THP-1,U-937 andMUTZ-3. In the studies that use
these DC cell models, the activation of endocytosis, the increase in
phosphotyrosine levels, the up-regulation of cell surface markers and the
increase in cytokine and chemokine productionwere analysed asmarkers
for the sensitisation capacity (dos Santos et al., 2009). In this context, our
work has been performed using a mouse skin-derived dendritic cell line,
FSDC, that is a model of immature DC, with morphological, phenotypical
and functional characteristics of Langerhans cells (Girolomoni et al.,
1995). In contrast to other DC lines used for studying skin sensitisation
hazards, FSDC have the advantage of being cultured in the absence of
exogenous recombinant growth factors.We observed that the sensitisers,
2,4-dinitroﬂuorobenzene (DNFB) and nickel, increased the expression of
themembrane-associated proteins CD40 and interleukin (IL) 12 receptor,
whereas the non/very weak skin sensitiser 2,4-dichloronitrobenzene
(DCNB) did not affect the expression of either protein (Vital et al., 2004;
Matos et al., 2005a). Recently, we also found that the CXCR4 chemokine
receptor is selectivelymodulated by skin sensitisers (and not by irritants)
in FSDC (Neves et al., 2008).
An extremely important, yet sometimes neglected, fact is that all
DC modiﬁcations triggered by skin sensitisers, both at the genomic
and proteomic levels, result from the coordination of different
intracellular signalling pathways that are speciﬁcally triggered by
skin sensitisers and not by irritants. Accordingly, the recently
formulated paradigm “Toxicity testing in the 21st century: A Vision
and a Strategy” (National Research Council, 2007) focuses on the
speciﬁc toxicity pathways linked to these endpoints rather than
speciﬁc cellular markers. We and other authors showed that contact
sensitisers activate the mitogen-activated protein kinases (MAPKs),
mainly the p38 MAPK (Matos et al., 2005a,b; Koeper et al., 2007;
Trompezinski et al., 2008). Moreover, we and other authors have
shown that further downstream signals elicited by skin sensitisers
include the activation of the transcription factors nuclear factor
kappa-B (NF-kB) and activating protein-1 (AP-1) (Cruz et al., 2002,
2004; Ade et al., 2007; Antonios et al., 2009). The following question
remains: whether all contact sensitisers use the same signal
transduction pathways as the stimuli known to induce DCmaturation,such as lipopolysaccharide, proinﬂammatory cytokines, or CD40
ligand, or whether there is an innate cellular signalling pathway
proﬁle activated only by skin sensitisers. A related question is whether
contact sensitisers can be classiﬁed on the basis of their signal
transduction proﬁles and if this proﬁle can be used to distinguish skin
sensitisers from nonspeciﬁc chemical irritants. There is a gap in this
issue, since few studies have addressed the impact of skin sensitisers
and irritants on the signal transduction proﬁle of skin cells, namely
dendritic cells and keratinocytes. Additional studies are required to
understand which signalling pathways function as sensors for skin
sensitisers and are responsible for the phenotypic and functional
modiﬁcations of dendritic cells that initiate the early events in the
development of ACD. The focus of this review is to summarise the
current status of the intracellular signalling pathways that are
activated in DC or DC-like cells upon exposure to skin sensitisers
and irritants.
Tyrosine phosphorylation
The work of Kuhn et al., (1998) was pioneering in the detection of
tyrosine phosphorylation induced by contact sensitisers in humanMHC
class II-positive antigen-presenting cells. The authors used different cell
types, namely human LC, immature fresh DC isolated from the blood,
monocytes, B cells andHLA-DRnegative cells alongwith several chemicals,
including strong sensitisers (DNFB, 5-chloro-2-methylisothiazolinone
plus 2-methylisothiazolinone, (MCI/MI), thimerosal and formalde-
hyde), weak sensitisers (methyl paraben, 2-phenoxyethanol) and the
irritants SDS and BC. Contact sensitisers increased tyrosine phosphor-
ylation exclusively in MHC class II-positive antigen-presenting cells.
Furthermore, only the strong sensitisers induced tyrosine phosphory-
lation in human blood-derived dendritic cells. In contrast, the weak
sensitiser phenoxyethanol and the irritants SDS and BC failed to
modulate tyrosinephosphorylation. Thisworkwas conﬁrmed inmurine
LC and a signiﬁcant increase in tyrosine phosphorylation was observed
in response to the strong sensitisers 2,4,6-trinitro-chlorobenzene
(TNCB) and MCI/MI, but not after cell treatment with the irritants SDS
and benzoic acid (Neisius et al., 1999).
Although we can conclude from these studies that the activation of
cellular tyrosine kinases cannot be used to distinguish sensitisers from
irritants, because the weak sensitisers tested did not increase tyrosine
phosphorylation, this assay could potentially be useful to detect
strong and extreme allergens.
Activation of protein kinase C (PKC)
The involvement of PKC on LCmigration from the epidermis was ﬁrst
demonstrated by the work of Halliday and Lucas (1993). The authors
observed that the topical application of an analogue of diacylglycerol, the
physiological activator of PKC, reduced the density of epidermal LC after
24 h using both BALB/c and C57BL mice. Additionally, LC migration from
the epidermis, induced by the contact sensitiser TNCB, was blockedwhen
PKC was inhibited by palmitoyl-DL-carnitine chloride or D-sphingosine,
indicating that LC cannot migrate from the epidermis when PKC is
inhibited. More recently, the work of Staquet et al. (2004) addressed the
migratory capacity of epidermal and in vitro-generated LC. They observed
that, in the presence of PKC inhibitors, Bandrowski's base- or 2,
4-dinitrobenzenesulfonic acid-induced LC migration was strongly
decreased.
Because LCmigration is a prerequisite for skin sensitisation, it would
be interesting to evaluate thedirect effect of skin sensitisers and irritants
on PKC activation in dendritic cells, whichwas not addressed until now.
Activation of the mitogen-activated protein kinases (MAPKs)
Different signalling pathways such as MAPKs and NF-kB play
important roles in DC maturation (Rescigno et al., 1998; Arrighi et al.,
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MAPKs p38 MAPK and extracellular signal-regulated kinases 1/2
(ERK1/2) are involved in a wide variety of cellular responses,
including proliferation, differentiation and apoptosis. The ERK1/2
pathway is most commonly linked to the regulation of cell
differentiation and survival, whereas JNK and p38 MAPK pathways,
usually referred to as stress-stimulated MAPKs, are activated by
various environmental stresses such as osmotic shock, UV radiation,
heat shock, oxidants and proinﬂammatory cytokines and are also
known to mediate apoptosis.
Arrighi et al. (2001) reported, for the ﬁrst time, that DC maturation
(observed as theup-regulation of CD80, CD86 andCD83) induced by the
contact sensitisers DNFB and nickel, was dependent upon p38 MAPK
phosphorylation and was inhibited by SB203580, a speciﬁc p38 MAPK
inhibitor. The irritants SDS and BC did not trigger p38 MAPK
phosphorylation. The results showed that p38 phosphorylation in DC
may be useful for the identiﬁcation of potential skin contact sensitisers.
The activation of p38 MAPK and ERK1/2 was also induced by the
sensitiser TNCB in DC (Bruchhausen et al., 2003) and MAPKs activation
by contact sensitisers was later conﬁrmed (Aiba et al., 2003). The
authors stimulatedhumanmonocyte-deriveddendritic cellswithnickel
and DNCB and observed that DNCB-induced p38 MAPK and JNK1/2
phosphorylation, whereas nickel-induced p38 MAPK, JNK1/2 and
ERK1/2 phosphorylation. In contrast, the irritants BC and SDS did not
activate these signal transduction pathways. By using speciﬁc inhibitors
for ERK and p38MAPKs pathways, PD98059 and SB203580, respective-
ly, the authors demonstrated that the DNCB-induced up-regulation of
CD86, HLA-DR, CD83 and IL-8 and the nickel-induced increase of CD83
and IL-12 p40 were mediated by the p38 MAPK pathway, whereas the
ERK pathway modulated the production of IL-1β and tumour necrosis
factor (TNF)-α in nickel treated-cells. The results showed that both
sensitisers stimulated different signal transduction pathways and
subsequently induced different phenotypic and functional changes in
DC. Accordingly, Iijima et al. (2003) demonstrated that TNF-α andDNCB
activate the p38 MAPK pathway at early and late phases, respectively
and thereby induce murine DC maturation through different signalling
pathways. The Pallardy group subsequently conﬁrmed the activation of
p38 MAPK by metallic haptens in dendritic cells (Ade et al., 2007;
Antonios et al., 2009); the authors reported that NiSO4 and CoCl2, but
not K2Cr2O7, activated theMAPKspathways and theNF-kB transcription
factor. In this work, p38 MAPK activation regulated the NiSO4-induced
CD86 and CD83 expression while it only affected the CoCl2-induced
CD83 expression. Moreover, the authors also reported that IL-6
production induced by NiSO4 and CoCl2 strongly depended on all
MAPKs, while NiSO4-induced IL-12p40 synthesis was only dependent
on p38 MAPK and JNK pathways. The results showed that both NiSO4
andCoCl2 activate similar signallingpathways that playdifferent roles in
DC maturation, depending on the hapten used. Recent studies also
showed that p38 MAPK is activated by NiSO4 in human monocyte-
derived DC and cooperates for IL-12 production (Antonios et al., 2010).
In human CD34+-derived DC, nickel activates p38 MAPK, ERK1/2 and
JNK, all of which are MAPKs involved in the expression of CD83, CD86
and CCR7 but not in the nickel-induced down-regulation of E-cadherin
and Langerin (Boisleve et al., 2005). TNF-αproduction inducedbyDNCB
was also linked to the activation of p38 MAPK and JNK (Boisleve et al.,
2004). In previous results performed with the foetal skin-derived
dendritic cell line (FSDC), we reported that DNFB activates p38 MAPK
and ERK1/2 via the production of reactive oxygen species and that
protein oxidation plays an important role inMAPKs activation (Matos et
al., 2005b). These results are in agreementwith the key role of oxidative
stress in the activation of MAPKs (Mizuashi et al., 2005; Hirota et al.,
2009; Suzuki et al., 2009; Kagatani et al., 2010).
The early intracellular mechanisms involved in DC maturation
were also addressed in other studies (Trompezinski et al., 2008). The
authors investigated whether MAPKs were induced by sensitisers
(nickel, DNCB or thimerosal) and the irritant SDS. They observed thatSDS did not induce changes in signalling pathways, whereas nickel,
DNCB and thimerosal markedly activated p38 MAPK and JNK. In
contrast, ERK1/2 phosphorylation was completely inhibited by DNCB
or thimerosal but only activated by nickel. Pre-treatment with the p38
MAPK inhibitor SB203580 suppressed the ERK1/2 inhibition induced
by DNCB or thimerosal, suggesting a direct interaction between p38
MAPK and ERK1/2 pathways.
The study of the activation of MAPKs by skin sensitisers was also
extended to other cell models, namely to skin explants and to the THP-1
monocytic cell line. Therefore,murine andhuman skin explants, aswell as
reconstituted skinmodels (epidermal model EST-1000 and full-thickness
model AST-2000), were exposed to sensitising (oxazolone and DNFB) or
irritant (SDS and TritonX-100) compounds andMAPKs (p38, ERK1/2 and
JNK1/2) phosphorylation, signal transducer and activator of transcription
(STAT) 1 and phospholipase C (PLC)-γ were evaluated (Koeper et al.,
2007). In skin explants, all three MAPKs were selectively activated after
exposure to sensitising compounds. For the reconstituted skin models,
p38 MAPK and JNK1/2 phosphorylation was stimulated by allergens,
whereas ERK1/2 activation was induced by treatment with irritants; the
activation of PLCγ and STAT1 were never detected. In two recent papers,
the authors addressed MAPKs activation induced by chemicals in the
THP-1 human monocytic cell line (Miyazawa et al., 2008; Nukada et al.,
2008) and the authors found that DNCB and nickel-induced p38 MAPK
and ERK phosphorylation. The inhibition of p38 MAPK activation
selectively blocked DNCB-induced TNF-α release, but not nickel-induced
release. In contrast, inhibition of the ERK pathway selectively suppressed
nickel-induced TNF-α release but not DNCB-induced release. In addition,
the authors found that the inhibition of the p38MAPK and ERK pathways
caused a selective down-regulation of CD86, CD54 and/or CD40
expressions. In particular, inhibition of p38 MAPK suppressed DNCB-
induced CD86, CD54 and CD40 expressions and nickel-induced CD86
expression, while inhibition of the ERK pathway suppressed CD86, CD54
and CD40 expressions induced by both allergens (Miyazawa et al., 2008).
The authors extended their work to include the chemokine IL-8 and
observed that the inhibition of ERK suppressed the DCNB- and nickel-
induced production of this interleukin, whereas the inhibition of p38
MAPK only suppressed the IL-8 production induced by DNCB (Nukada et
al., 2008). The results showed that both DNCB and nickel activate p38
MAPK and ERK in THP-1 cells and thereby stimulate phenotypic changes
through the different signal transduction pathways. Accordingly,
Megherbi and colleagues reported that DNFB activated p38 MAPK in the
THP-1 cell line, which is the signalling pathway responsible for the
observed changes in CD54 expression and IL-8 release (Megherbi et al.,
2009). The chemical-induced activation of MAPKs in THP-1 was further
conﬁrmed by Mitjans et al. (2008), who exposed THP-1 cells to contact
allergens (cinnamaldehyde, DNCB, nickel, penicillin G, p-phenylenedia-
mine and tetramethylthiuram disulﬁde) to respiratory allergens (ammo-
nium hexachloroplatinate, diphenylmethane diisocyanate and trimellitic
anhydride) and to irritants (salicylic acid, phenol and SDS) and
investigated if a common activation pathway in allergen-induced IL-8
production could be identiﬁed. They demonstrated that all chemical
allergens tested activated p38 MAPK and using its selective inhibitor
SB203580, a signiﬁcant modulation of induced IL-8 release was observed
in all cases. The results showed that the activationof p38MAPKrepresents
a commonpathway triggered by allergens (Mitjans et al., 2008). Recently,
the same group extended these observations and conclusions to a new
panel of sensitisers (p-benzoquinone, 2-aminophenol, isoeugenol, diethyl
maleate, citral and imidazolidinyl urea) and proposed the use of IL-8
release and p38 MAPK activation in THP-1 cells to identify allergens and
assess their potency in vitro (Mitjans et al., 2010).
Taken together, all of these data indicate that chemical sensitisers
differentially modulate MAPKs signalling pathways and p38 MAPK
seems to be the most promising signalling pathway for inclusion in a
potential in vitro test for skin sensitisation hazards. Accordingly, we
also observed in the FSDC cell line that p38 MAPK is a speciﬁc sensor
for skin sensitisers, because all of the sensitisers tested (nickel,
Table 1
Intracellular signalling pathways modulated by chemicals in DC or DC-like cells and its phenotypic/functional modiﬁcations.
Signalling pathway Chemical Type of
modulation
Phenotypic modiﬁcation References
JAK/STAT Sensitisers Antonios et al. (2010), Valk et al. (2002),






Nickel Activation IL-12 production
PKC Sensitisers Staquet et al. (2004), Halliday and Lucas (1993)
TNCB Not determined LC migration
DNBS
Brandrowski's base
Tyrosine phosphorylation Strong sensitisers Kuhn et al. (1998), Neisius et al. (1999)
DNFB Activation
MCI/MI Activation











Benzoic acid No modulation
NF-kB Sensitisers Ade et al. (2007), Aiba et al. (2003),
Antonios et al. (2009, 2010),
Cruz et al. (2002, 2004)











ERK Sensitisers Aiba et al. (2003), Antonios et al. (2009),
Arrighi et al. (2001), Boisleve et al. (2005),
Bruchhausen et al. (2003),
Matos et al. (2005a, 2005b),
Miyazawa et al. (2008), Nukada et al. (2008),
Trompezinski et al. (2008)
Nickel Activation Up-regulation of IL-6, IL-8, IL-1β, TNF-α,















JNK Sensitisers Aiba et al. (2003), Antonios et al. (2009, 2010),
Arrighi et al. (2001), Boisleve et al. (2004, 2005),
Trompezinski et al. (2008)
Nickel Contradictory
results













p38 MAPK Sensitisers Ade et al. (2007), Aiba et al. (2003),
Antonios et al. (2009, 2010), Arrighi et al. (2001),
Boisleve et al. (2004, 2005), Bruchhausen et al.
(2003), Iijima et al. (2003), Matos et al. (2005a,
2005b), Megherbi et al. (2009),
Mitjans et al. (2008, 2010), Miyazawa et al. (2008),
Nukada et al. (2008), Trompezinski et al. (2008)
Nickel Activation Up-regulation of CD80, CD83, CD86, CD54,
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Table 1 (continued)



















Propylene glycol No activation
Lactic acid No activation
Nrf2/ARE Sensitisers Ade et al. (2009), Lewis et al. (2006),



















Sensitisers Hirota et al. (2009), Kagatani et al. (2010),
Suzuki et al. (2009)Cell surface thiols DNCB Changes Up-regulation of CD86, CD83, HLA-DR, IL-8,

















Sensitisers Mizuashi et al. (2005)
DNCB, DNFB, DNBB,
DNIB and DNBS
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was in contrast to the effect observed for the irritants SDS and BC
(unpublished data). Concerning the other MAPKs, ERK and JNK, the
results from the literature are indeed sparse and contradictory
(Table 1); these differences may be due to different DC cell models
used in the experiments. In the FSDC cell line, JNK was indeed
activated by all skin sensitisers tested (nickel, oxazolone, DNFB, and
PPD) but not the irritants SDS and BC (unpublished data). Morestudies should be performed to evaluate the accuracy of JNK activation
in the discrimination between sensitisers and irritants.
Activation of Janus kinases (JAK)/STAT pathways
Cytokines are critical coordinators of the immune system and in
particular, the IL-12 family of cytokines (IL-12, IL-17, IL-23 and more
recently, IL-35) is a key player in the regulation of T cell responses,
92 B.M. Neves et al. / Toxicology and Applied Pharmacology 250 (2011) 87–95which is orchestrated by the monocytes, macrophages and dendritic
cells that produce the IL-12 family of cytokines in response to danger
signals. These cytokines activate similar members of the JAK/STAT
signalling pathway due to homology in their receptor components.
Therefore, it would be reasonable that skin sensitisers, recognised by
DC as danger signals, modulate the JAK/STAT pathway. Whether the
JAK/STAT signalling pathway is directly activated by contact sensi-
tisers in antigen-presenting cells was investigated in studies in which
human monocytes and monocyte-derived DC were stimulated with
the structurally unrelated contact sensitisers MCI/MI, thimerosal,
TNCB and formaldehyde and the phosphorylation of the transcription
factors STAT1, STAT3, STAT4, STAT5 and STAT6 was determined (Valk
et al., 2002). In contrast to the positive controls performed with
cytokines, hapten treatment did not stimulate a signiﬁcant increase in
STAT phosphorylation. These results showed that contact allergens do
not directly activate common JAK/STAT pathways. However, the
authors used short incubation periods (15 min) and it could be
speculated that although contact allergens did not directly activate
JAK/STAT, an effect on this signalling pathway may be observed with
longer incubation times, which corresponds to an autocrine effect of
cytokines released by DC in response to sensitisers. Recent studies
also showed that NiSO4 induces STAT1 phosphorylation on serine and
tyrosine residues that participate in NiSO4-induced IRF-1 activation in
human dendritic cells (Antonios et al., 2010). However, the authors
used longer incubation periods (2 to 4 h). Therefore, experiments
should be performed using cells stimulated with chemicals and
analysed for JAK/STAT after long incubation times.
Intracellular redox imbalance, changes in cell surface thiols and
glutathione depletion
The capacity of a small chemical compound to covalently bind to
protein structures or to form stable complexes with proteins is one
prerequisite to act as a hapten and a probable contact sensitiser.
Putative reaction mechanisms of contact allergens with cell amino
(lysine residues) and thiol (cysteine residues) groups have been
proposed and implicated in the induction of hypersensitivity. Such
direct interactions between haptens and thiol groups have been
shown in mercury compounds (Santucci et al., 1998) and MCI/MI
(Gruvberger and Bruze, 1998). The concept of protein binding was
already used to develop an assay based on chemicals binding to
cysteine-containing glutathione (Gerberick et al., 2004; Aptula et al.,
2006). However, this approach has some limitations, namely for pro-
haptens and should be completed with biological assays.
Other studies reported that in monocytes and monocyte-derived
dendritic cells, the increase in tyrosine phosphorylation induced by the
contact sensitisers TNCB and MCI/MI was dependent on its coupling to
thiol groups (Becker et al., 2003). Indeed, tyrosine phosphorylation
induced by strong sensitisers was completely prevented by cysteine but
not lysine, suggesting a competitive mechanism between cysteine and
the sulfhydryl groups of cell proteins. In these experiments, the authors
studied the capacity of different antioxidants (ascorbic acid, alpha-
tocopherol, pyrrolidine dithiocarbamate, N-acetylcysteine and glutathi-
one) to block the increase in tyrosine phosphorylation observed
after human monocyte stimulation with strong contact sensitisers
(Bruchhausen et al., 2003). The authors observed that only thiol
antioxidants, namely N-acetylcysteine and glutathione, blocked the
increase in tyrosine phosphorylation induced by the sensitisers and
concluded that the capacity of thiol antioxidants to block the binding of
contact sensitisers to their cellular target structures could be the
mechanism that prevents tyrosine phosphorylation. Accordingly, DNFB
induced a signiﬁcant increase in protein oxidation, as measured by the
formation of carbonyl groups, while it had almost no effect on lipid
peroxidation in the FSDC line. In addition, glutathione, but not vitamin E,
inhibited DNFB-induced p38MAPK and ERK1/2 phosphorylation (Matos
et al., 2005b). Whether sensitisers induce redox or oxidative stress indendritic cells was investigated by measuring the ratio of the oxidised
(GSSG) versus the reduced (GSH) form of cellular glutathione (Mizuashi
et al., 2005); all of the sensitisers (nickel, formaldehyde, DNCB, MnCl2,
and thimerosal), but none of the non-sensitisers (SDS, BC, and ZnCl2),
reduced the GSH/GSSG ratio, which was accompanied by p38 MAPK
phosphorylation. The antioxidant N-acetyl-L-cysteine, which suppressed
the reductionof theGSH/GSSG ratio, abrogatedboth thephosphorylation
of p38 MAPK and the augmentation of CD86 expression, a common
marker of the DC maturation induced by chemical sensitisers. The
authors suggested that the GSH/GSSG imbalance plays a crucial role in
triggering DC maturation by sensitisers. To identify the trigger for the
intracellular redox imbalance induced by sensitisers, studies were
performed to evaluate whether haptens directly or indirectly induce
THP-1maturation (Hirota et al., 2009). DNCB and nickel-induced related
changes in cell surface thiols and phosphorylation of p38 MAPK, in a
manner similar to that observed for an exogenous, cell-impermeable
thiol oxidiser. The effect of sensitisers on the oxidation of cell surface
thiolswas further investigated in humanmonocyte-derivedDC andTHP-
1 (Suzuki et al., 2009; Kagatani et al., 2010); all sensitisers tested
decreased cell surface thiols in parallel with phosphorylation of p38
MAPK and epicutaneous application of DNCB onmouse skin signiﬁcantly
decreased cell surface thiols of Langerhans cells in vivo. The results
showed that oxidation of cell surface thiols is one of the triggers of
dendritic cell maturation induced by haptens andmay be useful for an in
vitro sensitisation assay. A recent study showed that different dinitro-
halobenzenes (DNCB, DNFB, DNBB, DNIB andDNBS) deplete intracellular
glutathione to a similar extent in THP-1 cells (Megherbi et al., 2009).
However and in contrast with the observations of other authors, GSH
depletion via buthionine sulfoximine did not elicit cell maturation.
These in vitro approaches are corroborated with in vivo studies
demonstrating that DNCB reacts with glutathione and depleted thiols
in the viable epidermis following penetration through the stratum
corneum (Pickard et al., 2009). Furthermore, glutathione metabolism
in mice is preferentially enhanced in hapten-induced allergic contact
dermatitis rather than in irritant contact dermatitis (Hirai et al., 1997).
Althoughusing different approaches anddifferent cell types, all these
studies emphasisea crucial role for thiols in theprocessofDCmaturation
and in the subsequent development of ACD. In this context, changes in
cell surface thiols inducedby chemical sensitisers seemtobeapromising
output for integration into a testing strategy for skin sensitisation.
Activation of the NF-kB transcription factor
The NF-kB transcription factor plays an essential role in the
optimal activation of the host immune system. Various immune
responses in dendritic cells are positively regulated by NF-kB, such as
the production of inﬂammatorymediators, cytokines/chemokines and
the up-regulation of surface molecules (Kaisho and Tanaka, 2008). In
addition, the NF-kB signalling pathway is reported to be involved in
DC maturation (Rescigno et al., 1998; Arrighi et al., 2001; Aiba et al.,
2003; Boisleve et al., 2005; Neves et al., 2009). Indeed some of the
phenotypic and functional changes induced in DC by haptens are
dependent upon the activation of NF-kB. Previous results in the FSDC
line demonstrated that the sensitiser nickel activates the NF-kB and
AP-1 transcription factors, as measured by the electrophoretic
mobility shift assay (EMSA). Furthermore, DNFB differentially
activates the various members of the NF-kB family (Cruz et al.,
2002, 2004); three out of the ﬁve members, p50, p52 and RelB, were
similarly activated upon DNFB stimulation with subsequent translo-
cation of these subunits from the cytosol to the nucleus, althoughwith
different kinetics. In contrast, p65 expression was diminished in both
the nucleus and the cytosol, suggesting the eventual activation of a
non-canonical NF-kB pathway. None of the other skin sensitisers
tested in the FSDC line (oxazolone, PPD and nickel) induced the
degradation of IkB-α (unpublished data). In contrast with these
results, nickel-induced IkB-α phosphorylation and NF-kB activation in
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this pathway did not affect the induced phenotypic and functional
changes. The effect of nickel on NF-kB in humanmonocyte-derived DC
was speciﬁc, since no effect was observed in the presence of the
irritants BC or SLS. More recently, it was also demonstrated in human
dendritic cells that nickel, but not DNCB, activates the degradation of
IkB-α leading to the binding of the NF-kB p65 subunit to speciﬁc DNA
probes (Ade et al., 2007). NF-kB pathway inhibition using BAY
11-7085 prevents both CD40 and HLA-DR expression and cytokine
production but only partially inhibits nickel-induced CD86 and CD83
expressions. These results showed that modiﬁcations of the DC
phenotype induced by nickel, but not by DNCB, are probably the
consequence of NF-kB activation. This work was recently extended to
other metallic haptens, namely CoCl2 and K2Cr2O7 and the results
demonstrated that nickel and CoCl2, but not K2Cr2O7, activate the
NF-kB transcription factor in DC derived from CD34+ cord blood cells
(Antonios et al., 2009). Furthermore, p38 MAPK, NF-kB and IRF-1
were involved in nickel-induced IL-12p40 production in human
monocyte-derived DC (Antonios et al., 2010).
Taken together, these data indicate that although some sensitisers
activate the NF-kB transcription factor and are probably responsible
for some phenotypic modiﬁcations observed in DC, other sensitisers
failed to activate this signalling pathway. For the group of sensitising
chemicals that were unsuccessful in activating NF-kB, we can
speculate that the phenotypical modiﬁcations observed are probably
controlled by other signalling pathways and transcription factors,
such as MAPKs and NRF2, or alternatively, a non-canonical pathway of
NF-kB activation could be induced by allergens, as previously reported
with other dendritic cell antigens (Gregory et al., 2008).
Activation of the NRF2/ARE transcription factor signalling pathway
A signiﬁcant body of recent evidence indicates that the signalling
pathway involving the repressor protein Keap1 (Kelch-like ECH-
associated protein 1) and the transcription factor nuclear factor-
erythroid 2-related factor 2 (Nrf2), which binds to the antioxidant
response element (ARE) in the promoter region of many phase II
detoxiﬁcation genes, could be a potential marker of skin sensitisation
hazards. Indeed, the Nrf2/ARE regulatory pathway is one of the most
important cellular defence mechanisms against electrophilic stress,
because Keap1may be covalently modiﬁed by electrophiles leading to
the activation of ARE-dependent genes, such as thioredoxin, heme
oxygenase (decycling) 1 (HMOX1), NAD(P)H dehydrogenase quinone
1 (NQO1) and quinone reductase, which are involved in the
protection or neutralisation of chemical reactive species. Natsch and
Emter (2008) pioneered this ﬁeld and they evaluated whether this
regulatory pathway could be used to develop a predictive cellular in
vitro test for sensitisation. In this context, 96 different chemicals of
known skin sensitisation potential were added to Hepa1C1C7 cells
and the induction of the ARE-regulated quinone reductase (QR)
activity was determined. In parallel experiments, 102 chemicals were
tested in the AREc32 reporter cell line, which contains an eightfold
repeat of the ARE sequence upstream of a luciferase gene. Among the
strong/extreme skin sensitisers, 14 out of 15 and 30 out of 34
moderate sensitisers induced the ARE-dependent luciferase activity
and in many cases this response was paralleled by an induction of QR
activity in Hepa1C1C7 cells. Sixty percent of the weak sensitisers also
induced luciferase activity. Only 4 out of 30 tested non-sensitisers
induced low levels of luciferase activity. Overall, a prediction accuracy
of about 82% was achieved, which is only slightly lower than that
obtained during the validation of the local lymph node assay. In
another study, CD34-derived DC and the THP-1 myeloid cell line were
treated with a panel of sensitisers, irritants and a non-sensitiser
molecule (Ade et al., 2009). The expressions of HMOX1 and NQO1,
which are dependent on Nrf2 activation, were measured using real-
time PCR and cellular accumulation of Nrf2 was assessed by Westernblot analysis. The increased expressions of HMOX1 and NQO1 mRNAs
were observed at early time points in response to sensitisers (but not
to irritants) and the accumulation of the Nrf2 protein was also
observed only with chemical sensitisers. A signiﬁcant inhibition of the
expression of HMOX1 and NQO1 mRNAs and CD86 expression was
found in DNCB-treated THP-1 cells preincubated with N-acetyl
cysteine, a glutathione precursor. These results showed that electro-
philic molecules, including sensitisers, activated the Keap1/Nrf2-
signalling pathway in dendritic cells and in the THP-1 cell line.
Similarly, it was previously demonstrated that the skin sensitiser
nickel activates the Nrf2 signalling pathway in humanmonocytic cells
(Lewis et al., 2006) and our previous work demonstrated that
thioredoxin, a protein encoded by a gene containing an ARE element
in the promoter region, is involved in DC maturation (Francisco et al.,
2010). The effect of dinitrohalobenzenes in Nrf2 was also tested in
THP-1 cells, together with several other markers, namely for changes
in CD54 levels, IL-8 release, p38 MAPK phosphorylation and NF-kB
(Megherbi et al., 2009). Dinitrohalobenzenes failed to activate NF-kB
but activated Nrf2 and depleted intracellular glutathione. Further-
more, a new in vitro method, which combined the measurement of
glutathione depletion in a cell-free matrix with Keap1/Nrf2/ARE/
EpRE-mediated gene expression in human skin cells, showed promise
for identifying chemicals and metals that induce skin sensitisation
(McKim et al.). The Nrf2–Keap1–ARE regulatory pathway was
recently proposed as a toxicity pathway speciﬁcally activated by
cysteine-reactive compounds. Since electrophilicity is one of the most
common features of skin sensitisers and is responsible for protein
haptenation, it seems logical that electrophilic sensitisers activate the
Nrf2/ARE signalling pathway. Therefore, this signalling pathway
seems to be one of the most promising to sensor electrophilic skin
sensitisers. However, electrophilicity is not the only mechanism by
which chemicals can bind to proteins, since metallic sensitisers are
not electrophiles and thiol sensitisers are nucleophiles. Furthermore,
sensitisers, such as penicillin, that react with lysine residues appear to
not activate this pathway andmight trigger another unknown toxicity
pathway (Natsch, 2010). Indeed, penicillin did not elicit maturation,
Nrf2 activation or changes in GSH (Megherbi et al., 2009).
Conclusion and future prospects
Skin sensitisation is a complex biological phenomenon and it is
now accepted that non-animal alternatives for the assessment of the
sensitising potential of chemicals will require a combination of data
from different endpoints, to truly replicate the sensitisation process in
vitro. Among the favoured strategies are those based on the
modiﬁcations induced by chemicals in DC or DC-like cell models. All
of these modiﬁcations, both at the genomic and proteomic levels, are
the consequence of a coordinated orchestration of different intracel-
lular signalling pathways that are speciﬁcally triggered by skin
sensitisers and not by irritants. From the literature, we can point
out that, although different sensitisers stimulate different signal
transduction pathways, the most promising signalling pathways for a
platform of tests for skin sensitisation hazard are p38MAPK, Nrf2/ARE
and changes in cell surface thiols (Fig. 1). However, efforts are still
required to further optimise existing methods and eventually identify
more predictive signalling endpoints that have not yet been
addressed. Indeed, it is reasonable to speculate that some of these
predictive signalling endpoints may be downstream of the MAPKs
signalling pathway, such as Elk-1, c-jun, JunD, activating transcription
factor 2 (ATF-2) and cAMP response element-binding protein (CREB),
because all are involved in co-stimulatory and cytokines/chemokine
expression. Therefore, additional work is required to understand, in
detail, the transduction pathways triggered by chemical sensitisers
and to clarify the role of each pathway on the DC maturation/
activation process and, consequently, their involvement in the
development of ACD.
Fig. 1. Schematic view of the signalling pathways triggered by contact sensitisers in dendritic cells.
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